MET and non-small cell lung carcinoma: In fact, only 9 of 256 (3.52%) patients showed CTCs with high MET expression (scores of 2+ or 3+) in CellSearch®, whereas MET-positive CTCs from advanced-stage NSCLC patients were successfully detected using the ISET platform, being 54 of the 75 (72%) patients’ blood samples defined as MET positive.